CD68 and type 2 diabetes mellitus: We also measured the phagocytic capacity using Iba1-ir and CD68-ir co-staining and found no differences in CD68-ir content between T2DM and controls, suggesting similar microglial immune surveillance and phagocytic capacity (Fig. 3e–g).